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 Metabotropic GABAB receptors are 
abundantly expressed at glutamatergic 
synapses where they control excitability of the 
synapse. Here we tested the hypothesis that 
glutamatergic neurotransmission may feed 
back to regulate GABAB receptors. We found 
that application of glutamate to cultured 
cortical neurons led to rapid downregulation of 
GABAB receptors via lysosomal degradation. 
This effect was mimicked by selective activation 
of AMPA receptors and further accelerated by 
co-activation of group I metabotopic glutamate 
receptors. Inhibition of NMDA receptors, 
blockade of L-type Ca2+ channels and removal 
of extracellular Ca2+ prevented glutamate-
induced downregulation of GABAB receptors, 
indicating that Ca2+-influx plays a critical role. 
We further established that glutamate-induced 
downregulation depends on the internalization 
of GABAB receptors. Glutamate did not affect 
the rate of GABAB receptor endocytosis but led 
to reduced recycling of the receptors back to 
the plasma membrane. Blockade of lysosomal 
activity rescued receptor recycling, indicating 
that glutamate redirects GABAB receptors from 
the recycling to the degradation pathway. In 
conclusion, the data indicate that sustained 
activation of AMPA receptors downregulates 
GABAB receptors by sorting endocytosed 
GABAB receptors preferentially to lysosomes 
for degradation on expense of recyling. This 
mechanism may relieve glutamatergic synapses 
from GABAB receptor-mediated inhibition 
resulting in increased synaptic excitability. 
 
 In the mature mammalian nervous system 
excitatory neurotransmission mediated by 
glutamate is balanced by the inhibitory actions of 
GABA. Slow, prolonged inhibitory 
neurotransmission is largely mediated by 
metabotrophic GABAB receptors, which are 
widely expressed in the central nervous system 
and play an important role in many neurological 
disorders such as epilepsy, anxiety, depression, 
addiction and chronic pain (for a review, see Ref. 
(1)). Functional GABAB receptors are 
heterodimers composed of the two subunits 
GABAB1 and GABAB2 and expressed in brain as 
two receptors subtypes (GABAB(1a,2) and 
GABAB(1b,2)) based on alternative promoter usage 
of GABAB1. GABAB receptors are either localized 
at postsynaptic sites where they induce slow 
inhibitory postsynaptic potentials by activating K+ 
channels or at presynaptic sites where they 
suppress neurotransmitter release by inhibiting 
Ca2+ channels (for a review, see Ref. (1)).  
 GABAB receptors are not only localized at 
GABAergic synapses but are also abundantly 
expressed at glutamatergic synapses (2-5). At 
these synapses they are activated by GABA 
spillover derived from sustained GABAergic 
neurotransmission (6) and control glutamatergic 
activity at pre- and postsynaptic sites (7-11). There 
is accumulating evidence that sustained activation 
of glutamate receptors in turn may affect GABAB 
receptors. Treatment of cultured cortical neurons 
with glutamate resulted in the loss of cell surface 
GABAB receptors (12) and NMDA-induced 
excitotoxicity in hippocampal slices led to 
increased GABAB1 and decreased GABAB2 
expression levels (13). In addition, it was reported 
that glutamate slows the rate of GABAB receptor 
endocytosis in cultured hippocampal neurons (14). 
These findings suggest that sustained 
glutamatergic activity may regulate the availability 
of GABAB receptors, which in turn is expected to 
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affect excitability of glutamatergic synapses. 
However the mechanisms involved in this putative 
regulation of GABAB receptors by glutamate 
remain to be established. 
 Previously, we had shown that endocytosed 
GABAB receptors are predominantly recycled 
back to the plasma membrane and are eventually 
degraded in lysosomes (15). Recycling and 
degradation of GABAB receptors needs to be 
precisely balanced to maintain the required 
number of receptors at the cell surface. On the 
other hand, shifting the balance towards 
degradation would be a powerful mechanism to 
downregulate GABAB receptors. Here we tested 
the hypothesis that sustained activation of 
glutamate receptors might affect GABAB receptor 
levels by regulating their rate of recycling and 
degradation. We found that treating cultured 
cortical neurons with glutamate resulted in a rapid 
downregulation of GABAB receptors. The 
glutamate-induced downregulation was triggered 
by sustained activation of AMPA receptors, 
depended on Ca2+ influx through NMDA receptors 
as well as L-type Ca2+ channels and finally 
resulted in reduced constitutive recycling and 
increased lysosomal degradation of GABAB 
receptors.  
 
EXPERIMENTAL PROCEDURES 
 Antibodies – The following primary antibodies 
were used: rabbit GABAB1a,b directed against the 
C-terminus of GABAB1 (affinity-purified, 1:500 
for In Cell Western assay, immunofluorescence 
and Western blotting; for specificity see (16); 
custom-made by GenScript), guinea pig GABAB2 
(1:1000 for immunofluorescence and 1:2000 for 
Western blotting, Chemicon International), rabbit 
GABAB2-F(ab’)2 directed against the N-terminus 
of GABAB2 (1:50 for internalization and recycling 
assays; for specificity see (17); custom-made by 
GenScript), mouse actin (1:1000 for In Cell 
Western assay and 1:80,000 for Western blotting, 
Chemicon International), rabbit GABAA receptor 
directed against the N-terminus of the α1 subunit 
(affinity purified, 1:100 for In Cell Western assay 
(18)), mouse PSD95 (1:500 for 
immunofluorescence, Affinity Bioreagents), rabbit 
PSD95 (1:2000 for immunofluorescence), guinea 
pig vGlut1 (1:10,000 for immunofluorescence, 
Chemicon International), rabbit vGlut1 (1:10,000 
for immunofluorescence, Synaptic Systems). 
Secondary antibodies were coupled either to Alexa 
Fluor 488 (1:1000, Invitrogen), Cy-3 (1:500, 
Jackson ImmunoResearch), IRDye®680 (1:800, 
LI-COR Biosciences), IRDye®800CW (1:200, LI-
COR Biosciences) or horseradish peroxidase 
(1:5000, Jackson ImmunoResearch). 
 Drugs – ω-Agatoxin TK (0.5 µM, Tocris 
Bioscience), AMPA (100 µM, Tocris Bioscience), 
bafilomycin A1 (0.5 μM, Sigma-Aldrich), 
chloroquine (100 μM, Sigma-Aldrich), CNQX (20 
µM, Tocris Bioscience), ω-conotoxin GVIA (3 
µM, Sigma-Aldrich), ω-conotoxin MVIIC (2 µM, 
Tocris Bioscience), D-AP5 (50 µM, Tocris 
Bioscience), DCG IV (100 µM, Tocris 
Bioscience), dynasore (100 µM, Sigma-Aldrich), 
glycine (10 µM, Sigma-Aldrich), glutamate (50 
µM, Sigma-Aldrich), L-AP4 (100 µM, Tocris 
Bioscience), leupeptin (100 µM, Sigma-Aldrich), 
MG 132 (10 µM, Sigma-Aldrich), monensin (50 
μM, Sigma-Aldrich), nifedipine (100 µM, Tocris 
Bioscience), NASPM (10-250 µM, Sigma-
Aldrich) , NMDA (100 µM, Tocris Bioscience), 
tADA (200 µM, Sigma-Aldrich), UBEI-45 (50 
µM, Biogenova). 
 Cell Culture – Primary neuronal cultures of 
cerebral cortex were prepared from E18 embryos 
of time-pregnant Wistar rats as described 
previously (15). Neurons were plated to a density 
of about 30,000 cells onto poly-L lysine coated 
96-well plates or 60,000 cells onto poly-L lysine 
coated coverslips, respectively. Neurons were kept 
in culture at 37 °C and 5% CO2 for 11 to 21 days. 
The vast majority of experiments were performed 
with cultures kept for 11-16 days in vitro and a 
few experiments were done with older cultures (up 
to 21 days in culture). Since the results derived 
from the older cultures were similar to those 
obtained from younger cultures the data were 
pooled. 
Western Blotting – Western blot experiments using 
GABAB1a,b and GABAB2 antibodies were 
performed with cortical neurons grown on 6 cm 
culture dishes (about 2.5 x 106 cells per dish) as 
described previously (15). 
 Immunocytochemisty and Confocal Laser 
Scanning Microscopy – Double labeling 
immunocytochemistry on cortical neurons cultured 
on coverslips was performed as described 
previously (15,19). Incubation with primary 
antibodies diluted to the appropriate concentration 
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in PBS containing 10% normal goat serum was 
done for 1h at room temperature. After embedding 
in fluorescence mounting medium 
(DakoCytomation) neurons were analyzed by 
confocal laser scanning microscopy (LSM510 
Meta; Zeiss) using a 100x plan apochromat oil 
differential interference contrast objectitve (1.4 
NA). Images were acquired at a resolution of 1024 
x 1024 pixels in the sequential mode. For each 
neuron 5 optical sections spaced by 0.38 µm were 
taken. Images were processed using Imaris 
(version 4.2.0 and 5.7.2, Bitplane, Zurich, 
Switzerland). 
 For colocalizaion studies on dendrites of 
cortical neurons, raw confocal images were 
smoothed using the Edge Preserving Filter (filter 
width 0.636 µm) and then further processed by 
setting threshold cutoffs for each image 
individually to only visualize significant signals 
above background. Individual thresholds cutoffs 
accounted for differences in background staining 
among distinct neurons and dendrites. A 
colocalization channel was built (colocalization 
intensity 255, constant value) and GABAB 
receptor and synaptic marker protein clusters (>15 
pixels) as well as their colocalization were counted 
within 10 µm of the dendrite beginning at a 
distance of 10 µm from the soma. In addition, the 
width of the dendrite was measured to calculate 
the area analyzed. 
 Quantification of fluorescence intensities was 
done using the Image J software 
(http://www.macbiophotonics.ca/imagej/index.htm
). For the analysis of GABAB receptor expression 
the soma excluding the nucleus of stained neurons 
was carefully outlined and the integrated density 
of the fluorescence signals measured. For 
quantification of cell surface GABAB receptors the 
integrated density of the fluorescence signals 
derived from the surface of living stained neurons 
was determined. Background fluorescence was 
determined for each image and subtracted. 
 In Cell Western Assay – For the In Cell Western 
assay neurons were cultured in 96-well plates. On 
the day of testing the culture medium was 
removed and replaced by 100 μl neurobasal 
medium containing B27 supplement (1:50, 
Invitrogen), GlutaMAX (1:100, Invitrogen) and 
the drug to be tested. Cultures were incubated in 
the presence or absence of the drug for 90 min at 
37 °C and 5% CO2. Thereafter, the neurons were 
rapidly cooled to 4°C, washed twice with ice-cold 
PBS and fixed with 4% paraformaldehyde (PFA) 
for 10 min. Subsequently, cells were 
permeabilized four times for 5 min with 0.1% 
Triton-X-100 (Sigma-Aldrich) in PBS and then 
incubated with 5% non-fat dry milk in PBS for 2 h 
at room temperature to block nonspecific antibody 
binding sites. Cultures were then incubated for 24-
48 h simultaneously with rabbit GABAB1a,b and 
mouse actin antibodies (in PBS, 5% non-fat dry 
milk). Non-specific GABAB1a,b antibody binding 
was assessed in parallel cultures by competition 
using the peptide-antigen (10 µg/ml). 
Subsequently, neurons were extensively washed 
with 0.1% Tween 20 (Sigma-Aldrich) in PBS and 
incubated with the appropriate secondary 
antibodies (IRDye680 goat anti-mouse; 
IRDye800CW donkey anti-rabbit) in PBS 
containing 5% non fat dry milk for 60 min at room 
temperature protected from light. After washing 
the neurons with 0.1% Tween 20 in PBS and once 
with PBS the buffer was completely removed and 
the fluorescence was measured with the Odyssey 
Infrared Imaging System (LI-COR Biosciences). 
 Data evaluation: Integrated fluorescence 
intensities for non-specific GABAB1a,b signals (as 
assessed by competition with the peptide antigen) 
were determined in multiple wells, averaged and 
subtracted from GABAB1a,b signals. Obtained 
specific GABAB1a,b signals were then normalized 
to the actin signal determined in parallel to 
account for potential cell loss during washing 
steps or unequal plating of neurons.  
 Internalization Assay – Cortical neurons grown 
in 96-well plates were rapidly cooled to 4°C and 
washed with ice-cold buffer A (25 mM HEPES, 
pH 7.4, 119 mM NaCl, 5 mM KCl, 2 mM CaCl2, 2 
mM MgCl2, 30 mM glucose). Cell surface GABAB 
receptors were then labeled by incubation with 
GABAB2-F(ab’)2 antibodies in buffer A containing 
10% normal donkey serum for 60 min at 4 °C. 
After extensive washing with buffer A, the 
neurons were incubated for 1.5 - 15 min at 37°C to 
permit internalization of the receptors in the 
absence or presence of glutamate (50 µM). 
Control cultures for determining the total cell 
surface GABAB receptors were left at 4°C, a 
condition that is non-permissive for internalization. 
After washing with ice-cold buffer A, the cultures 
were incubated with IRDye800CW donkey anti-
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rabbit secondary antibody in buffer A for 90 min 
at 4°C. To account for potential cell loss during 
washing steps or unequal plating of neurons, 
cultures were incubated in parallel with the cell-
permeant nuclear stain DRAQ5 (1:1000, Biostatus 
Limited). After extensive washing, the buffer was 
completely removed and the fluorescence of dry 
cultures was measured with the Odyssey Infrared 
Imaging System. Non-specific GABAB2-F(ab’)2 
antibody signals were determined by competition 
with the peptide-antigen (10 µg/ml) in multiple 
wells. DRAQ5 signals were used for 
normalization. For data evaluation see In Cell 
Western.  
 Recycling Assay – Cell surface GABAB 
receptors of cortical neurons grown in 96-well 
plates were labeled with GABAB2-F(ab’)2 
antibodies as described above for the 
internalization assay. For internalization of labeled 
receptors, cultures were incubated for 15 min at 
37°C. Thereafter, the neurons were incubated for 
60 min at 4 °C with a secondary antibody (Alexa 
Fluor 488-conjugated, 1:50, Invitrogen) that is not 
detected by the infrared imaging system and is 
used to mask primary antibodies that labeled 
remaining cell surface GABAB receptors. After 
washing, the neurons were again incubated for 30 
min at 37°C to permit internalized antibody-
labeled receptors to recycle back to the cell surface. 
Recycled receptors were then detected at the cell 
surface using IRDye800CW donkey anti-rabbit 
secondary antibodies and cultures were processed 
further as described above for the internalization 
assay. 
 
RESULTS 
 Sustained Activation of Glutamate Receptors 
Triggers Lysosomal Degradation of GABAB 
Receptors - To investigate whether modulation of 
neuronal activity regulates degradation of GABAB 
receptors, cultured cortical neurons grown in 96-
well plates were incubated for 90 min with 
agonists and antagonists of the main 
neurotransmitter systems and were analyzed for 
changes in GABAB receptor expression using the 
In Cell Western assay. Among the drugs tested 
(not shown), only glutamate and AMPA led to a 
significant reduction of GABAB receptor signals in 
cultured neurons with glutamate being more 
effective than AMPA (90 min glutamate: 46 ± 
14%, AMPA: 64 ± 13% of control; Fig. 1A). 
Immunofluorescence microscopy showed that 
levels of GABAB1 and GABAB2 subunits were 
downregulated to a similar extent by glutamate (30 
min glutamate, GABAB1: 57 ± 20%, GABAB2: 53 
± 17% of control, n=33-48 neurons; Fig. 1B). 
Furthermore, Western blot experiments 
demonstrated that GABAB1a and GABAB1b 
receptor subtypes were equally affected by 
glutamate (90 min glutamate, GABAB1a: 42 ± 6%, 
GABAB1b: 43 ± 12% of control, mean ± SD, n=5-6 
cultures, Fig. 1E). The glutamate-induced 
downregulation of GABAB receptors was not due 
to reduced viability of neurons upon drug 
exposure since no significant cell death was 
observed within the time frame of the experiment 
(control: 0.4 ± 0.6 %, 90 min glutamate: 0.9 ± 
0.9 %, mean ± SD, n=22 cultures; trypan blue dye 
exclusion assay). Glutamate-induced 
downregulation of GABAB receptors was found to 
be dose-dependent with 5 µM glutamate triggering 
the half-maximal effect (Fig. 1C). Glutamate did 
not affect expression of GABAA receptors, 
indicating that it specifically downregulates 
GABAB receptors (Fig. 1D).  
 We had previously shown that GABAB 
receptors are degraded in lysosomes (15,19). 
Therefore we tested the hypothesis that activation 
of glutamate receptors triggers lysosomal 
degradation of GABAB receptors. Indeed, blocking 
lysosomal proteases with leupetin resulted in a 
decreased glutamate-induced downregulation of 
GABAB receptors, as shown by Western blot 
analysis (GABAB1a: glutamate: 42 ± 6%, 
glutamate + leupetin: 79 ± 18%; GABAB1b: 
glutamate: 43 ± 12%, glutamate + leupetin: 71 ± 
16%; GABAB2: glutamate: 65 ± 10%, glutamate + 
leupetin: 105 ± 19% of control; mean ± SD, n= 5-
6 cultures, Fig. 1E). Surprisingly, also the 
proteasome inhibitor MG132 inhibited glutamate-
induced downregulation of GABAB receptors 
(GABAB1a: 73 ± 8%; GABAB1b: 70 ± 19%; 
GABAB2: 103 ± 29% of control; mean ± SD, n= 5-
6 cultures, Fig. 1E). This finding ostensibly 
suggests that GABAB receptors may also be 
degraded by proteasomes. However, experiments 
with proteasome inhibitors are difficult to interpret 
since blocking proteasomal activity rapidly results 
in the depletion of free ubiquitin. Ubiquitin not 
only tags proteins for proteasomal degradation but 
also serves as sorting signal to lysosomes for many 
proteins. If the proteasome directly contributes to 
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the degradation of GABAB receptors it is expected 
that simultaneous inhibition of proteasomes and 
lysosomes would block GABAB receptor 
downregulation to a greater extent than inhibition 
of each degradation pathway alone. However, 
incubation of neurons simultaneously with 
leupeptin and MG132 did not result in an 
increased inhibition of glutamate-induced GABAB 
receptor degradation (Fig. 1F). Therefore, it is 
unlikely that the proteasome directly contributes to 
the degradation of GABAB receptors. Instead, this 
finding suggests that ubiquitin may serve as 
lysosomal targeting signal for endocytosed 
GABAB receptors. Blocking ubiquitination using 
the ubiquitin-activating enzyme (E1) inhibitor 
UBEI-45 partially inhibited glutamate-induced 
downregulation of GABAB receptors (Fig. 1F) 
indicating that ubiquitination is a critical factor in 
this process. 
 Glutamate-Induced Downregulation of GABAB 
Receptors is Mediated by AMPA Receptors and 
Accelerated by Type I Metabotropic Glutamate 
Receptors – Since AMPA largely mimicks the 
effect of glutamate (Fig. 1A), AMPA receptors 
appear to primarily trigger the downregulation of 
GABAB receptors. However, although the AMPA 
receptor antagonist CNQX fully inhibited AMPA-
induced downregulation of GABAB receptors it 
only partially reversed glutamate-induced 
downregulation (Fig. 2A). This result indicates 
that also other glutamate receptors than AMPA 
receptors may contribute to this effect. 
Surprisingly, the selective NMDA receptor 
antagonist D-AP5 completely reversed glutamate-
induced GABAB receptor downregulation (Fig. 
2A) although application of NMDA/glycine did 
not affect GABAB receptor levels (Fig. 1A). 
Because NMDA receptors are blocked by Mg2+ 
around resting potential, this apparent discrepancy 
may be caused by a too low basal AMPA receptor 
activity in unstimulated cultures to permit 
sufficient activation of NMDA receptors. In 
conclusion, the results indicate that in addition to 
AMPA receptors also NMDA receptors are 
involved in glutamate-induced downregulation of 
GABAB receptors. 
 The observation that treatment of neurons for 
90 minutes with AMPA induced less reduction of 
GABAB receptors than application of glutamate 
(Fig. 1A) suggests either that activation of AMPA 
receptors alone is not able to mediate the 
maximum effect or that glutamate more efficiently 
downregulates GABAB receptors than AMPA. A 
time course of glutamate and AMPA application 
revealed that both drugs led to a similar maximum 
reduction of GABAB receptors but glutamate more 
rapidly downregulated GABAB receptors 
(glutamate t1/2 = 25 ± 13 min, AMPA t1/2 = 49 ± 17 
min; Fig. 2B).  
 Since the NMDA receptor antagonist D-AP5 
reversed glutamate-induced downregulation of 
GABAB receptors (Fig. 2A), we hypothesized that 
activation of NMDA receptors in addition to 
AMPA receptors might accelerate this process. 
However, coapplication of AMPA and 
NMDA/glycine (or NMDA/D-serine, not shown) 
did not result in a further decrease GABAB 
receptor levels (Fig. 2C). Next we tested whether 
metabotropic glutamate receptors (mGluRs) may 
accelerate AMPA-induced downregulation of 
GABAB receptors. Indeed, coapplication of the 
selective mGluR1/5 agonist tADA with AMPA 
decreased GABAB receptors to the levels observed 
after glutamate treatment, while tADA was 
ineffective to downregulate GABAB receptors in 
the absence of AMPA (Fig. 2D). In contrast, 
coactivation of either group II mGluRs with DCG-
IV or group III mGluRs with L-AP4 did not 
enhance AMPA-induced GABAB receptors 
degradation (Fig. 2E). These results indicate that 
the sustained activation of AMPA and NMDA 
receptors is required for the downregulation of 
GABAB receptors, which is accelerated by 
additional activation of mGluR1/5. 
 Glutamate-Induced Downregulation Depends 
on Ca2+ Influx Through L-Type Voltage-Gated 
Ca2+ Channels – So far our data indicate that 
glutamate-induced downregulation of GABAB 
receptors involves activation of AMPA and 
NMDA receptors which both are permeable for 
Ca2+. Therefore, we hypothesized that Ca2+-influx 
may be required for this effect. As expected, 
removal of extracellular Ca2+ using EGTA 
completely inhibited glutamate and AMPA-
induced downregulation of GABAB receptors (Fig. 
3A). Next we tested whether Ca2+-influx through 
Ca2+-permeable AMPA receptors (AMPA 
receptors lacking GluR2) is required for 
downregulation of GABAB receptors. NASPM, a 
selective antagonist for Ca2+-permeable AMPA 
receptors, did not affect downregulation of 
GABAB receptors up to 100 µM (Fig. 3B). 
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However, at 250 µM NASPM inhibited glutamate-
induced downregulation of GABAB receptors (not 
shown). At this high concentration NASPM has 
been reported also blocking Ca2+-impermeable 
AMPA receptors (20). Thus, our results suggest 
that AMPA receptors containing the GluR2 
subunit, which are impermeable to Ca2+, mediate 
the downregulation of GABAB receptors. 
 Since AMPA receptors activate voltage-
dependent Ca2+ channels we tested whether Ca2+-
influx through these channels is required for 
downregulation of GABAB receptors. Inhibition of 
L-type Ca2+ channels with nifipidine completely 
prevented downregulation of GABAB receptors. In 
contrast, blocking P/Q-type and N-Type Ca2+ 
channels with ω-conotoxin MVIIC or inhibiting 
selectively P/Q-type or N-type Ca2+ channels with 
ω-agatoxin TK and ω-conotoxin GVIA, 
respectively, was without effect (Fig. 3B). These 
observations suggest that glutamate-induced 
downregulation of GABAB receptors depends on 
the activity of L-type Ca2+ channels. 
 Glutamate Affects Recycling but not 
Internalization of GABAB Receptors – One 
potential mechanism that may contribute to the 
downregulation of GABAB receptors might 
involve an increased rate of GABAB receptor 
endocytosis. We therefore tested first whether 
downregulation of GABAB receptors depends on 
the internalization of the receptors. We had 
previously shown that GABAB receptors 
internalize via the classical dynamin- and clathrin-
dependent pathway (19). As expected, inhibition 
of dynamin with dynasore completely blocked the 
glutamate-induced downregulation of GABAB 
receptors, indicating that endocytosis of receptors 
from the plasma membrane is required for the 
downregulation of GABAB receptors (Fig. 4A). 
However, application of glutamate did not affect 
the rate of GABAB receptor internalization 
(control: t1/2=1.6 ± 0.7 min, glutamate: t1/2=1.5 ± 
0.6 min; Fig. 4B).  
 Since GABAB receptors are constitutively 
recycled back to the plasma membrane (15) 
glutamate may instead interfere with recycling of 
the receptors. Indeed, treatment of neurons with 
glutamate significantly reduced recycling of 
internalized receptors back to the cell surface (Fig. 
4C). The reduced recycling was reversed by 
blocking lysosomal activity with leupeptin, 
indicating that receptors are preferentially sorted 
to lysosomes after glutamate application without 
direct inhibition of the recycling pathway (Fig. 
4C). This result was confirmed by directly 
interfering with receptor recycling using monensin, 
which blocks fusion of intracellular vesicles with 
the plasma membrane. Application of monensin 
resulted in the downregulation of cell surface 
GABAB receptors to the same extent as observed 
after glutamate treatment (Fig. 4D). However, the 
downregulation elicited by glutamate but not the 
downregulation induced by monensin was rescued 
by various blockers of lysosomal activity 
(leupeptin, chloroquine, bafilomycin A1, Fig. 4D). 
This result indicates that sustained glutamate 
application shifts the balance between recycling 
and degradation towards receptor degradation. 
 Glutamate Induces the Downregulation of 
Synapse-Associated GABAB Receptors – To 
analyze whether GABAB receptors localized at 
glutamatergic synapses are downregulated we 
performed immunofluorescence colocalization 
experiments using antibodies directed against 
GABAB1 (Fig. 5A) or GABAB2 (Fig. 5B) and 
antibodies against glutamatergic postsynaptic sites 
(PSD95) or glutamatergic presynaptic sites 
(vGlut1), respectively. Treatment of neurons for 
30 min with glutamate resulted in a dramatic loss 
(about 50%) of GABAB1 and GABAB2 clusters 
associated with either PSD95 (Fig. 5A1, B1) or 
vGlut1 (Fig. 5A2, B2). GABAB receptor clusters 
not associated with pre- or postsynaptic marker 
proteins (which also include intracellular 
receptors) were found to be reduced to a lesser 
extent (about 30%, Fig. 5A3, B3). The total 
number of PSD95 (Fig. 5A4, B4) and vGlut1 
clusters (Fig. 5A5, B5) was not affected by 
glutamate. These results suggest that GABAB 
receptors associated with synapses may be 
preferentially downregulated. 
 
DISCUSSION 
 GABAB receptors are abundantly localized at 
glutamatergic synapses to regulate excitatory 
neurotransmission. In this study we tested the 
hypothesis that glutamatergic activity may in turn 
feed back to regulate GABAB receptors. Such a 
mechanism had been suggested by Vargas et al. 
(12) based on their finding that treating neurons 
with glutamate resulted in a reduction of plasma 
membrane GABAB receptors. Our results indicate 
that sustained activation of AMPA receptors in 
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cultured cortical neurons leads to a rapid and 
dramatic downregulation of GABAB receptors by 
shifting the balance of constitutive recycling and 
lysosomal degradation towards degradation.  
 Treatment of neurons with glutamate led to a 
rapid decrease of the levels of both GABAB 
receptor subtypes, GABAB(1a,2) and GABAB(1b,2), 
expressed in neurons. Immunofluorescence 
analysis showed a slightly stronger loss of GABAB 
receptor clusters colocalized with marker proteins 
for glutamtergic synapses than not colocalizing 
GABAB receptor clusters, suggesting that GABAB 
receptors associated with synapses might be 
preferentially downregulated. The limited 
resolution of this method permits however no 
conclusion on whether pre- or postsynaptic 
GABAB receptors are affected to different extent.  
Glutamate activates a variety of distinct receptors, 
such as AMPA receptors, NMDA receptors and 
mGluRs1/5, which all mediate or contribute to 
downregulation of GABAB receptors. We found 
that selective activation of AMPA receptors 
mimicked the effect of glutamate but was less 
efficient in downregulating GABAB receptors, i. e. 
activating selectively AMPA receptors required 
more time to reach the same level of 
downregulation than after glutamate treatment. 
Simultaneous activation of mGluRs1/5 (group I 
mGluRs) accelerated AMPA-induced 
downregulation of GABAB receptors to the level 
of glutamate-induced downregulation, whereas 
coactivation of group II or group III mGluRs had 
no effect. Group I mGluRs are predominantly 
localized postsynaptically and generally promote 
cell excitability (21). Thus, activation of group I 
mGluRs in addition to AMPA receptors may 
further increase excitation of the neuron 
accelerating downregulation of GABAB receptors 
and explain the difference in time course of 
GABAB receptor downregulation by glutamate and 
AMPA (Fig. 2B). In addition to AMPA receptors 
and mGluRs1/5 also NMDA receptors play a 
critical role. Although treatment of neurons with 
NMDA and glycine (or D-serine) did not induce 
downregulation of GABAB receptors, blocking 
NMDA receptors with D-AP5 completely blocked 
the effects of glutamate (Fig. 2A) and AMPA (not 
shown). Basal AMPA receptor activity in 
unstimulated cultures may be too low to permit 
sufficient activation of NMDA receptors (which 
are blocked by Mg2+ at resting potential) by 
administration of NMDA and glycine to induce 
downregulation of GABAB receptors. Thus, our 
data indicate that the minimum requirement for 
glutamate-induced downregulation of GABAB 
receptors is the sustained activation of AMPA and 
NMDA receptors.  
 So far, the intracellular second messenger 
pathway(s) linking AMPA and NMDA receptor 
activation to GABAB receptor downregulation 
remains to be established. Because removal of 
extracellular Ca2+ by EGTA and inhibition of L-
type, but not P/Q and N-type, Ca2+ channels 
blocked GABAB receptor downregulation it is 
very likely that influx and intracellular 
accumulation of Ca2+ is one component of the 
intracellular signaling cascade. However, our first 
attempts to identify further components involved 
were unsuccessful so far. Activation or inhibition 
of major classical protein kinases such as protein 
kinase A, protein kinase C, Ca2+ calmodulin-
dependent kinase II (CaMKII) or blocking the 
Ca2+-dependent phosphatase calcineurin failed to 
affect glutamate-induced downregulation of 
GABAB receptors (not shown). Thus, further work 
is required to dissect the intracellular signaling 
pathway(s) involved. 
 Endocytosis and sorting mechanisms critically 
determine the availability of cell surface receptors 
for signal transduction. We therefore hypothesized 
that sustained activation of glutamate receptors 
might affect endocytosis of GABAB receptors. 
Blocking endocytosis with the dynamin inhibitor 
dynasore completely prevented downregulation of 
GABAB receptors. This result implies that constant 
internalization of cell surface GABAB receptors is 
required for downregulation. Since GABAB 
receptors are rapidly endocytosed and 
constitutively recycled back to the plasma 
membrane in neurons (12,15) downregulation of 
receptors can principally be achieved by either 
increasing the rate of internalization or affecting 
recycling. Our results indicate that the 
internalization rate of GABAB receptors remained 
unaffected upon glutamate administration. This is 
in contrast to a previous report indicating that 
glutamate administration to hippocampal neurons 
slowed the internalization rate of GABAB 
receptors tagged with the α-bungarotoxin binding 
site (14). The reason for this discrepancy is 
currently unknown but may be caused by the 
different assay systems used (e.g. endogenous 
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versus transfected receptors). However, while 
glutamate did not impair endocytosis of GABAB 
receptors it affected the extent of their recycling in 
our experimental settings. Impaired receptor 
recycling may shift the balance between recycling 
and degradation of the receptors in favor of 
degradation as recently shown for the transferrin 
receptor (22). However, this appears not to be the 
underlying mechanism for the glutamate-induced 
downregulation of GABAB receptors. Although 
directly blocking recycling with monensin resulted 
in a similar extent of GABAB receptor 
downregulation as glutamate treatment, inhibition 
of lysosomal activity prevented glutamate-induced 
but not monensin-induced downregulation of cell 
surface receptors. This result suggests that 
glutamate treatment does not directly block 
recycling of the receptors but affects the balance 
of sorting endocytosed GABAB receptors to 
recycling endosomes and lysosomes. 
 Regarding the involved degradation pathways 
we found that glutamate-induced downregulation 
was inhibited by blocking lysosomal as well as 
proteasomal activity by leupeptin and MG 132, 
respectively. In principle, this observation may 
suggest that the major protein degradation systems, 
lysosomes and proteasomes, are involved in 
downregulation of GABAB receptors. However, it 
is rather unlikely that the proteasome is directly 
involved in glutamate-induced degradation of the 
receptors since the blocking effects of leupeptin 
and MG 132 did not add up. Inhibition of 
proteasomes rapidly results in the depletion of free 
ubiquitin, which is also required as a lysosomal 
targeting signal for many proteins. Therefore, 
inhibiton of proteasomes with MG 132 most likely 
interferes with ubiquitin-dependent sorting to 
lysosomes. This interpretation is supported by the 
observation that sorting of GABAB receptors to 
lysosomes appears to involve the ESCRT 
(endosomal sorting complex required for 
transport) machinery (23) that targets mono- and 
Lys63-linked poly-ubiquitinated proteins for 
degradation to lysosomes (24). Our finding that 
interfering with protein ubiquitination by blocking 
the ubiquitin-activating enzyme (E1) reduces 
glutamate-induced downregulation of GABAB 
receptors documents the importance of 
ubiquitination in this process. However, it is 
currently unclear at what level ubiquitination may 
be involved. Ubiquitination may operate at 
different levels such as endocytosis, sorting and/or 
lysosomal targeting and may require direct 
ubiquitination of the receptors or of proteins 
involved in these processes or both. This issue 
needs to be delineated in further studies. 
 Based on our observations, we propose that 
sustained activation of AMPA receptors triggers 
the opening of NMDA receptors and L-type Ca2+ 
channels which leads to an intracellular 
accumulation of Ca2+. An as yet to be established, 
most likely Ca2+-dependent, signaling pathway 
shifts the balance between constitutive recycling 
and lysosomal degradation of GABAB receptors 
towards degradation without affecting the rate of 
receptor internalization. Since all components 
required for glutamate-induced downregulation of 
GABAB receptors are mainly colocalized 
postsynaptically (25,26) we propose that glutamate 
may preferentially downregulate GABAB 
receptors associated with postsynaptic sites. In 
particular the fact that N-type and P/Q-type Ca2+ 
channels, which are predominantly associated with 
presynaptic sites (25,26), appear not to be 
involved in downregulating GABAB receptors 
supports this hypothesis.  
 The physiological relevance of glutamate-
induced downregulation of GABAB receptors 
remains to be determined. Two obvious scenarios 
can be envisioned: 1) under pathophysiological 
condition, excessive release of glutamate leads to 
over-stimulation of AMPA and NMDA receptors 
and eventually to neuronal death (27). In this 
context glutamate induced downregulation of 
GABAB receptors will result in reduced inhibition 
of glutamatergic synapses, which is expected to 
further promote excitotoxicity. 2) Under normal 
physiological conditions, GABAB receptors 
associated with glutamatergic synapses control 
excitability of the synapse and thereby activity of 
NMDA receptors (28,29). Sustained stimulation of 
individual glutamatergic synapses will 
downregulate its associated GABAB receptors and 
relieves the synapse from inhibition. This is 
expected to result in locally increased synaptic 
excitability. 
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aminobutyric acid type B; mGluR, metabotropic glutamate receptor; NMDA, N-methyl-D-aspartate; 
PSD95, postsynaptic density protein 95; vGlut1, vesicular glutamate transporter 1.  
 
FIGURE LEGENDS 
 
FIGURE 1. Sustained activation of glutamate receptors induces the downregulation of GABAB 
receptors via lysosomal degradation. 
A) Downregulation of GABAB receptors is triggered by glutamate and AMPA. Primary cortical neurons 
were treated either with 50 μM glutamate, 100 μM AMPA or 100 μM NMDA + 10 μM glycine for 90 
min and tested for GABAB receptor levels using the In Cell Western assay and antibodies directed against 
the C-terminus of GABAB1. Mean ± SD; n=20-40 cultures from 3-5 preparations, ***= p<0.001, one way 
ANOVA, Bonferoni post test.  
B) Glutamate downregulates GABAB1 and GABAB2 as verified by immunocytochemistry. For 
immunofluorescence analysis, cells were treated with 50 μM glutamate for 30 min. This incubation time 
resulted in sufficient remaining fluorescence signals in the glutamate treated cultures enabling a reliable 
quantification. After fixation and permeabilization neurons were stained with antibodies directed against 
GABAB1 and GABAB2, respectively. Representative confocal images. B’) Quantification of fluorescence 
signals. Scale bar represents 10 µm. Mean ± SD; n=33-48 neurons from 3 preparations, ***= p<0.0001, t-
test. 
C) Dose-dependency of glutamate-induced downregulation of GABAB receptors. Neurons were treated 
with increasing concentrations of glutamate for 90 min and analyzed for GABAB receptor levels using the 
In Cell Western assay and GABAB1 antibodies. A concentration of 5 μM glutamate led to half-maximal 
downregulation of GABAB receptors. Mean ± SD; n=20 cultures from 3 preparations. 
D) Glutamate does not affect expression levels of GABAA receptors. Neurons were subjected to 50 μM 
glutamate for 90 min and analyzed for GABAB and GABAA receptor levels using the In Cell Western 
assay and antibodies directed against GABAB1 and the GABAA receptor α1 subunit, respectively. Mean ± 
SD; n=40-60 cultures from 5 preparations, ***= p<0.0001, n.s.: p=0.8, t-test. 
E) Glutamate-induced downregulation is prevented by lysosome and proteasome inhibitors. Neurons were 
treated with 50 µM glutamate in the presence or absence of the lysosome blocker leupeptin (100 μM) or 
the proteasome blocker MG 132 (10 μM), solubilized and analyzed for GABAB receptor levels by 
Western blotting using GABAB1 and GABAB2 antibodies. GABAB1a and GABA1b isoforms as well as 
GABAB2 subunits were downregulated after glutamate treatment. Downregulation was blocked by the 
lysosomes inhibitor leupeptin and by the proteasome inhibitor MG132. Bands present in the middle of the 
blot were observed at varying intensities and most likely represents degradation products of GABAB 
receptors. The experiment shown was repeated once with three cultures for each condition. E’) 
Quantification of the Western blots. Mean ± SD; n=46 cultures, n.s.= p>0.05, *=p<0.05, **=p<0.01 ***= 
p<0.001, one way ANOVA, Dunnett’s post test. 
F) The proteasome is most likely not directly involved in downregulating GABAB receptors. Neurons 
were treated for 90 min with 50 µM glutamate in the presence or absence of the lysosome blocker 
leupeptin (100 μM), the proteasome blocker MG 132 (10 μM) or a combination of both. In addition, the 
involvement of ubiquitination was tested by treating neurons with the ubiquitin-activating enzyme (E1) 
inhibitor UBEI-45 (50 µM). GABAB receptor levels were determined using the In Cell Western assay and 
GABAB1 antibodies. Since the effects of leupeptin and MG132 did not add-up it is unlikely that GABAB 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on Novem
ber 2, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
11 
receptors are degraded by proteasomes. Mean ± SD; n=40-48 cultures from 4 preparations, n.s.= p>0.05, 
**=p<0.01 ***= p<0.001, one way ANOVA, Bonferoni post test. 
 
FIGURE 2. Glutamate-induced downregulation of GABAB receptors is mediated by AMPA 
receptors and accelerated by type I mGluRs. 
A) Glutamate-induced downregulation of GABAB receptors is partially reversed by the AMPA antagonist 
CNQX and fully reversed by the NMDA antagonist D-AP5. Cells were treated for 90 min either with 50 
μM glutamate, 100 μM AMPA, 20 μM CNQX, 50 μM D-AP5 or with the indicated combinations and 
tested for GABAB receptor levels using the In Cell Western assay and antibodies directed against the C-
terminus of GABAB1. Mean ± SD; n=27-44 cultures from 3-5 preparations, **=p<0.01, ***= p<0.001, 
one way ANOVA, Bonferoni post test.  
B) Selective activation of AMPA receptors mimics the effect of glutamate but is less efficient in 
downregulating GABAB receptors. Neurons were incubated with 50 μM glutamate or 100 µM AMPA and 
were analyzed for GABAB receptor levels at different time points (10 min to 6 h) using the In Cell 
Western assay. Data were fitted to one phase exponential decay: glutamate, t1/2=25 ± 13 min; AMPA, 
t1/2=49 ± 17 min. Mean ± SD; n=12 cultures from 3 preparations,  
C-E) Combined activation of AMPA and mGluR group I receptors (D), but not AMPA and NMDA (C) 
or mGluR group II or III receptors (E), mimic glutamate induced downregulation of GABAB receptors. 
Neurons were incubated for 90 min with either 50 μM glutamate, 100 μM AMPA, 100 μM NMDA + 10 
μM glycine, 200 μM tADA (mGluR1/5 agonist), 100 μM L-AP4 (mGluR4/6/7/8 agonist) or 100 μM 
DCGIV (mGluR2/3 agonist) alone or with the indicated combinations. Mean ± SD; C: n=24 cultures from 
3 preparations, D: n=21 cultures from 3 preparations, D: n=32 cultures from 4 preparations. n.s.=p>0.05, 
**=p<0.01, ***= p<0.001, one way ANOVA, Bonferoni post test (C and D) or Dunnetts post test (E).  
 
FIGURE 3. Ca2+ influx through voltage-gated Ca2+ channels is necessary for glutamate-induced 
downregulation of GABAB receptors. 
A) Removal of extracellular Ca2+ using EGTA completely inhibited glutamate and AMPA-induced 
downregulation of GABAB receptors. Cells were treated with either 50 μM glutamate, 100 μM AMPA or 
5 mM EGTA or with the indicated combinations for 90 min and tested for GABAB receptor levels using 
the In Cell Western assay. Mean ± SD; n=25-32 cultures from 4 preparations, ***= p<0.001, one way 
ANOVA, Bonferoni post test.  
B) Inhibition of L-type Ca2+ channels but not P/Q-type and N-type channels prevents downregulation of 
GABAB receptors. Neurons were incubated for 90 min either with 50 μM glutamate, 50 µM glutamate 
+100 µM NASPM (blocker of Ca2+-permeable AMPA receptors) +100 μM nifepidine (L-type Ca2+ 
channel blocker), +2 µM ω-conotoxin MVIIC (P/Q and N-type Ca2+ channel blocker), +0.5 µM ω-
Agatoxin TK (P/Q-type Ca2+ channel blocker) or +3 µM ω-conotoxin GVIA (N-type Ca2+ channel 
blocker) and subjected to the In Cell Western assay for determination of GABAB receptor levels. Mean ± 
SD, n=16-32 cultures from 2-4 preparations, n.s.=p>0.05, ***= p<0.001, one way ANOVA, Bonferoni 
post test. 
 
FIGURE 4. Glutamate affects recycling but not internalization of GABAB receptors. 
A) Inhibition of dynamin with dynasore completely blocks the glutamate-induced downregulation of 
GABAB receptors. Neurons were treated either with 50 μM glutamate, 100 μM dynasore or with 50 μM 
glutamate + 100 μM dynasore for 90 min and subjected to the In Cell Western assay for determination of 
GABAB receptor levels. Mean ± SD, n=40 cultures from 5 preparations, ***= p<0.001, one way ANOVA, 
Bonferoni post test. 
B) Glutamate did not affect the rate of GABAB receptor internalization. Cell surface receptors of neurons 
were labeled at 4 °C for 60 min with F(ab’)2 fragments of an antibody directed against the N-terminus of 
GABAB2. Neurons were then incubated for 1.5 - 15 min at 37 °C in the presence or absence of 50 μM 
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glutamate followed by determination of cell surface GABAB receptor levels. Mean ± SD; glutamate: n=18 
cultures, 3 preparations; AMPA: n=12 cultures, 2 preparations. 
C) Glutamate reduces recycling of internalized receptors back to the cell surface. Cell surface receptors of 
neurons were labeled as described above and neurons were incubated for 15 min at 37 °C in the presence 
or absence of 50 μM glutamate, 100 μM leupeptin or 50 μM glutamate + 100 μM leupeptin to allow 
internalization of receptors. After masking remaining antibody-tagged cell surface receptors with 
secondary antibodies not detected by the imaging system neurons were incubated again for 30 min at 
37°C to allow internalized receptors to recycle back to the plasma membrane. Recycled receptors were 
detected using an appropriate labeled secondary antibody for 90 min at 4 °C. Mean ± SEM, n=30-94 
cultures from 4-9 preparations, ***= p<0.001, one way ANOVA, Bonferoni post test. 
D) Glutamate shifts the balance of GABAB receptor recycling and lysosomal degradation towards 
degradation without blocking recycling. Neurons were incubated for 1 h with 100 μM leupeptin, 100 μM 
chloroquine or 0.5 μM bafilomycin A1 before inducing downregulation of GABAB receptors by 50 μM 
glutamate or 50 μM monensin (blocks recycling by preventing fusion of intracellular vesicles with the 
plasma membrane) for 90 min. Living neurons were subsequently incubated with an antibody directed 
against the N-terminus of GABAB2 to label cell surface receptors and further processed for 
immunocytochemistry. Cell surface fluorescence signals of individual neurons were quantified. Control: 
no treatment. Mean ± SEM, n=31-81 neurons derived from two to four independent experiments, n.s. = 
p>0.05, **=p<0.01, one way ANOVA, Dunnett’s post test. 
 
 
FIGURE 5. GABAB receptors associated with synapses are downregulated by activation of 
glutamate receptors. Neurons were incubated in the presence or absence of 50 μM glutamate for 30 min, 
fixed and subjected to double labeling immunocytochemistry using antibodies directed against GABAB1 
(A, green) or GABAB2 (B, green) and antibodies against glutamatergic postsynaptic sites (PSD95, red) or 
glutamatergic presynaptic sites (vGlut1, red), respectively. Large images depict overviews of 
immunoreactivities in dendrites of lower magnification (scale bars: 5 µm) and the small images below 
show sections of dendrites after being processed for counting of clusters at high magnification (see 
Experimental Procedures for details; scale bars: 1 µm). In the absence of glutamate GABAB clusters 
frequently colocalized (yellow, arrowheads) with either pre- or postsynaptic markers. Glutamate 
treatment resulted in a significant loss of GABAB1 and GABAB2 clusters associated with either PSD95 
(A1, B1) or vGlut1 (A2, B2). GABAB receptor clusters not associated with pre- or postsynaptic marker 
proteins (which also include intracellular receptors) were found to be reduced to a lesser extent (A3, B3). 
The number of PSD95 (A4, B4) and vGlut1 (A5, B5) clusters was not affected by glutamate. Mean ± 
SEM, n=24 neurons derived from two independent experiments. **=p<0.01, ***= p<0.001, t-test. 
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